Abstract:Current therapies for pulmonary arterial hypertension (PAH) mainly focus on the abnormalities in the prostacyclin, nitric oxide and endothelin pathways. These drugs fail to markedly improve morbidity and mortality, and thereby identification of novel druggable targets is still critically needed for effective treatment of PAH in patients. Our previous studies have identified the prerequisite role of HIF-2α activation in mediating obliterative pulmonary vascular remodeling and development of severe PAH (Dai, Circulation 2016), suggesting that targeting HIF-2α represents a novel strategy for the treatment of severe PAH. Our recent data showed that endothelial HIF-2α and its downstream targets are activated in IPAH patients. Pharmacological inhibition of HIF-2α with a novel HIF-2α-selective inhibitor markedly reduced right ventricle systolic pressure (RVSP) and RV hypertrophy and prevented right heart failure as well as inhibited pulmonary vascular remodeling in mice with Tie2Cre-mediated deletion of Egln1, which is the first mouse model of severe PAH recapitulating many of the characteristic features of clinical PAH including vascular occlusion and plexiform-like lesions as well as right heart failure. This compound also inhibited RVSP and RV hypertrophy and thereby PAH in rats challenged with Sugen 5416/Hypoxia. Together, these studies for the first time demonstrate that targeting HIF-2α is a promising therapeutic strategy for effective treatment of PAH and thereby promoting survival. Support or Funding Information NIH grants R01HL123957, R01HL125350, R01HL133951, and P01HL077806 (Project 3) to Y.Y.Z, AHA postdoctoral fellowship grant 15POST25700124 to Z.D. Activation of endothelial HIF-2a and its downstream targets in IPAH patients. (A) QRT-PCR analysis demonstrating increased of HIF-2a and its target genes in the lung of IPAH patients compared to that of normal donor. (B) Immunofluorescent staining showing increase of endothelial HIF-2a expression in the luminal side of pulmonary arterial of IPAH. V, vessels. *, p<0.05. HIF-2a inhibitors suppressed HIF-2a activation. (A) Luciferase assay showing that HIF-2a antagonist-2 (H2A) and HIF-2a translation inhibitor compound 76 (C76) inhibited DMOG (1mM) induced HIF activation in HLMECs. (B) Luciferase assay demonstrating that both H2A and C76 suppressed PHD2 silencing induced HIF activation in HLMECs. (C) QRT-PCR analysis showed that C76 selectively inhibited HIF-2a targets CXCL12, PDGFB, GREM1 but not CXCR4. *, P<0.05. ***, ###, P<0.001. Pharmacological inhibition of HIF-2a in severe PAH mouse model. (A) Strategy of C76 treatment in Egln1Tie2 mice. (B) Dramatic decrease of RVSP in C76 treated Egln1Tie2 mice. (C) Marked inhibition of RV hypertrophy in C76 treated Egln1Tie2 mice. (D)Echocardiography showing normalization of PA function by C76 treatment. (E) (F) Echocardiography measurement demonstrating increase of PA AT and PA AT/ET ratio in C76 treated Egln1Tie2 mice. **P<0.01; ***P<0.001. Normalization of pulmonary vasculature pathology and molecules by HIF-2a inhibition. (A) Representative Russel Movat pentachrome staining showing reduction of neointima, decrease of wall thickness and adventitia by in C76 treated Egln1Tie2 mice. (B) (C) Anti-a-SMA staining demonstrating decrease of distal pulmonary arterial muscularization in C76 treated Egln1Tie2 mice. (D) QRT-PCR analysis demonstrating normalization of PH-causing genes by C76 treatment in Egln1Tie2 mice. HIF-2a inhibitor inhibited RV hypertrophy and prevented RV failure. (A) (B) Echocardiography showing decrease of RV wall thickness in C76 treated Egln1Tie2 mice. (C) (D) Representative WGA staining showing that C76 decreased cardiomyocyte hypertrophy in vivo. (E) Trichrome staining showing reduction of RV fibrosis by C76. (F) Echocardiography showing restoration of RV fraction area change in C76 treated Egln1Tie2 mice. (G) Reduced mortality by C76 treatment in Egln1Tie2 mice.

Therapeutic efficacy of the novel selective RNA polymerase I inhibitor CX‐5461 on pulmonary arterial hypertension and associated vascular remodelling

Endothelial Progenitor Cell-Based Therapy for Pulmonary Arterial Hypertension

Interruption of CD40 Pathway Improves Efficacy of Transplanted Endothelial Progenitor Cells in Monocrotaline Induced Pulmonary Arterial Hypertension.

Therapeutic Targeting of RNA Polymerase I With the Small-Molecule CX-5461 for Prevention of Arterial Injury-Induced Neointimal Hyperplasia.

The Selective RNA Polymerase I Inhibitor CX-5461 Mitigates Neointimal Remodeling in a Modified Model of Rat Aortic Transplantation

Therapeutic Targeting of Vascular Remodeling and Right Heart Failure in Pulmonary Arterial Hypertension with a HIF-2α Inhibitor.

Anti-fibrotic Effects of P53 Activation Induced by RNA Polymerase I Inhibitor in Primary Cardiac Fibroblasts.

A novel PDGFR inhibitor WQ-C-401 prevents pulmonary vascular remodeling in rats with monocrotaline-induced pulmonary arterial hypertension

Alleviating experimental pulmonary hypertension<i> via</i> co-delivering FoxO1 stimulus and apoptosis activator to hyperproliferating pulmonary arteries

Discovery of Novel Pyrazolo[3,4- b ] Pyridine Derivatives with Dual Activities of Vascular Remodeling Inhibition and Vasodilation for the Treatment of Pulmonary Arterial Hypertension

Selective Targeting HIF‐2α for Treatment of Pulmonary Arterial Hypertension

Inhibition of CXCR4 ameliorates hypoxia-induced pulmonary arterial hypertension in rats.

Targeting ADORA-PDE10 cAMP Microdomain: A Novel Therapeutic Approach for Pulmonary Hypertension

Inhibition of Src activation reverses pulmonary vascular remodeling in experimental pulmonary arterial hypertension via Akt/mTOR/HIF-1<alpha> signaling pathway.

Novel Tryptophan Hydroxylase Inhibitor TPT-001 Reverses PAH, Vascular Remodeling, and Proliferative-Proinflammatory Gene Expression

Retracted : CD248 as a novel therapeutic target in pulmonary arterial hypertension

Targeting sphingosine kinase 1 for the treatment of pulmonary arterial hypertension.

Established pulmonary hypertension in rats was reversed by a combination of a HIF‐2α antagonist and a p53 agonist

C-C motif chemokine receptor-2 blockade ameliorates pulmonary hypertension in rats and synergizes with a pulmonary vasodilator

siRNA Targeting ECE-1 Partially Reverses Pulmonary Arterial Hypertensionassociated Damage in a Monocrotaline Model

Ranolazine As a Novel Therapy for Pulmonary Arterial Hypertension.